The Experts below are selected from a list of 243 Experts worldwide ranked by ideXlab platform
Lisa R. Gerak - One of the best experts on this subject based on the ideXlab platform.
-
Discriminative stimulus effects of Nalbuphine in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics, 1996Co-Authors: Lisa R. GerakAbstract:Three rhesus monkeys discriminated between 0.178 mg/kg of Nalbuphine and saline while responding under a fixed-ratio 5 schedule of stimulus-shock termination. Nalbuphine produced dose-related increases in drug-lever responding with > or = 90% of responses occurring on the drug lever at doses larger than 0.1 mg/kg. The duration of action of the discriminative stimulus effects of Nalbuphine was less than 5.25 hr. Rank order potency of compounds that substituted for the Nalbuphine discriminative stimulus (i.e., > or = 90% responding on the Nalbuphine lever) in all three subjects was fentanyl > butorphanol > methadone > morphine. Compounds that did not substitute completely in all monkeys included the kappa agonists ethylketocyclazocine, enadoline, spiradoline and U-50,488 and the nonopioids cocaine, d-amphetamine, clonidine, ketamine and phencyclidine. Naltrexone antagonized the discriminative stimulus effects of Nalbuphine, shifting the Nalbuphine dose-effect curve in a manner that was consistent with mu receptor mediation. Results from the current study demonstrate that, in rhesus monkeys, the discriminative stimulus effects of Nalbuphine are mediated by mu opioid receptors. Although there is evidence suggesting that Nalbuphine has kappa agonist effects (e.g., subjective effects in humans), results from several studies, including the current study, strongly suggest that in rhesus monkeys Nalbuphine does not exert agonist actions at kappa receptors. Moreover, these data indicate that differences in behavioral effects between Nalbuphine and prototypic mu opioids (e.g., morphine) probably result from differences in activity (e.g., efficacy) at mu receptors rather than any kappa agonist actions of Nalbuphine.
-
Changes in sensitivity to the rate-decreasing effects of opioids in pigeons treated acutely or chronically with Nalbuphine.
Behavioural pharmacology, 1996Co-Authors: Lisa R. GerakAbstract:This study examined whether tolerance or dependence develops to the effects of the low-efficacy µ opioid agonist Nalbuphine on schedule-controlled responding. In untreated pigeons responding under a fixed ratio (FR)-20 schedule of food presentation, Nalbuphine, naltrexone, morphine, fentanyl, etonitazene and enadoline decreased response rates. Naltrexone (0.1-10.0mg/kg) did not antagonize the rate-decreasing effects of Nalbuphine. In a separate group of pigeons, chronic Nalbuphine treatment (1.0-56.0mg/kg/day) did not alter the sensitivity of pigeons to the rate-decreasing effects of Nalbuphine or naltrexone. In pigeons treated with 56.0mg/kg/day of Nalbuphine, dose-effect curves for µ and kappa agonists were shifted 3- to 10-fold to the right of dose-effect curves determined prior to chronic treatment. The rate-decreasing effects of Nalbuphine did not appear to be mediated by opioid receptors, as evidenced by the inability of naltrexone to antagonize Nalbuphine and the lack of tolerance development. Although chronic Nalbuphine altered the sensitivity to the rate-decreasing effects of µ and kappa agonists, there was no change in sensitivity to naltrexone. To the extent that increased sensitivity to antagonists is indicative of dependence, these data suggest that opioid dependence does not develop to Nalbuphine.
-
Antinociceptive and respiratory effects of Nalbuphine in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics, 1994Co-Authors: Lisa R. Gerak, E. R. Butelman, J. H. WoodsAbstract:Antinociceptive and respiratory effects of Nalbuphine and other opioids were studied in rhesus monkeys. In a thermal, tail withdrawal assay, the kappa agonist enadoline and the mu agonists alfentanil and fentanyl produced maximum antinociceptive effects in all subjects and over a wide range of temperatures, whereas Nalbuphine produced antinociceptive effects in only some subjects and only when the water temperature was < or = 50 degrees C. Naltrexone antagonized the antinociceptive effects of Nalbuphine, alfentanil and enadoline; however, the magnitude of antagonism was not equal among agonists. In subjects that did not show an antinociceptive response to Nalbuphine, Nalbuphine (3.2-10.0 mg/kg) antagonized the antinociceptive effects of fentanyl but not enadoline. The irreversible opioid antagonist clocinnamox produced a parallel shift to the right in the Nalbuphine dose-effect curve 1 hr after administration and decreased the maximum effect produced by Nalbuphine 24 and 48 hr after administration. Nalbuphine had modest respiratory-depressant effects in monkeys breathing air and attenuated hyperventilation produced by 5% CO2. In contrast, alfentanil had marked respiratory-depressant effects in monkeys breathing air or 5% CO2 in air and these effects were antagonized by Nalbuphine. Taken together, these results suggest Nalbuphine has low efficacy at mu opioid receptors; however, quantitative differences between alfentanil and Nalbuphine indicate a second (non-enadoline sensitive) receptor might also be important for the antinociceptive effects of Nalbuphine.
Heng Wang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of Nalbuphine and sufentanil for colonoscopy a randomized controlled trial
PLOS ONE, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p<0.05). The incidence of nausea was significantly higher in the Nalbuphine groups than in the sufentanil group in the first 24 hours after colonoscopy (p<0.05). Conclusions Nalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1–0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make Nalbuphine suitable for patients with respiratory problems.
-
Comparison of Nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.
PloS one, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p
Chaoyi Deng - One of the best experts on this subject based on the ideXlab platform.
-
comparison of Nalbuphine and sufentanil for colonoscopy a randomized controlled trial
PLOS ONE, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p<0.05). The incidence of nausea was significantly higher in the Nalbuphine groups than in the sufentanil group in the first 24 hours after colonoscopy (p<0.05). Conclusions Nalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1–0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make Nalbuphine suitable for patients with respiratory problems.
-
Comparison of Nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.
PloS one, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p
Jinlin Yang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of Nalbuphine and sufentanil for colonoscopy a randomized controlled trial
PLOS ONE, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p<0.05). The incidence of nausea was significantly higher in the Nalbuphine groups than in the sufentanil group in the first 24 hours after colonoscopy (p<0.05). Conclusions Nalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1–0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make Nalbuphine suitable for patients with respiratory problems.
-
Comparison of Nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.
PloS one, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p
Yanming Kang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of Nalbuphine and sufentanil for colonoscopy a randomized controlled trial
PLOS ONE, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p<0.05). The incidence of nausea was significantly higher in the Nalbuphine groups than in the sufentanil group in the first 24 hours after colonoscopy (p<0.05). Conclusions Nalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1–0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make Nalbuphine suitable for patients with respiratory problems.
-
Comparison of Nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.
PloS one, 2017Co-Authors: Chaoyi Deng, Xiao Wang, Qianmei Zhu, Yanming Kang, Jinlin Yang, Heng WangAbstract:Objectives Nalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of Nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of Nalbuphine in this indication. Methods Two hundred and forty consecutive eligible patients aged 18–65 years with an American Society of Anesthesiologists classification of I–II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), Nalbuphine 0.1 mg/kg (group N1), Nalbuphine 0.15 mg/kg (group N2), or Nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy. Results There was no significant difference in analgesia between the sufentanil group and the Nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p
